Introduction:

New World Evidence Market was valued at US$ 1.9 billion in 2024 and is projected to grow at a CAGR of 6.1% to reach US$ 7.2 billion by 2034.

The New World Evidence Data Market focuses on providing data regarding the patient’s health status and healthcare by collecting evidence from various sources, including real-world and clinical evidence regarding the usage, risks, and benefits of a medical product derived through the analysis of real-world data (RWD).

The rising prevalence of the geriatric population, as well as chronic diseases across the population, is the major factor boosting the growth of the target market. The growing burden of patients suffering from various chronic diseases increases the requirement and demand for smart data storage, thereby leading to the growth of the New World Evidence Data Market.

For instance, in 2016, according to the Health IT Buzz, it was reported that nearly 96% of hospitals and 78% of doctors in the United States had been using certified electronic health record systems.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Numerous Collaborations and Innovations in this Domain to fuel the target market growth

Growing innovations and collaborations made by numerous organizations in this domain, is one of the key factors boosting the growth of the New World Evidence Data Market. For instance, in May 2021, five companies - Aetion, IQVIA, Flatiron Health, Tempus, and Syapse teamed up together to leverage data from EHRs, claims, and other sources outside of clinical trials. To support broader efforts surrounding RWE, the coalition also decided to work with pharmaceutical firms, medical device producers, patient organizations, and other significant stakeholders.

New Product Developments and Launches to boost the market growth

New product developments and launches in this domain is another key factor boosting the growth of the New World Evidence Data Market. For instance, in 2021, according to the International Organization for Pharmacoeconomics and Outcomes Research (a US-based professional organization for health economics and outcomes research), the Real-World Evidence Transparency Initiative created the Real-World Evidence Registry. The Real-World Evidence Transparency Initiative aids in resolving possible issues with RWE studies by introducing the RWE registry and fostering a culture of transparency for the analysis and reporting of RWE (Real-World Evidence) in healthcare and research.

Restrains:

Numerous risks associated with data quality are one of the major factors restraining the growth of the New World Evidence Data Market. As data complexity increases, other data-quality issues also appear, which may restrict RWE's usage. For instance, it might be difficult to identify biases in the data and other underlying quality problems, which may restrict the conclusions drawn from such data. Additionally, the introduction of sophisticated analytics brings forth unique problems.

New World Evidence Data Market is segmented based on Component, Therapeutic Area, End-User, and Region.

Component Insight

On the basis of Component, New World Evidence Data Market is segmented into Dataset (Claims, Clinical, Pharmacy, and Patient) And Services. The Services component segment is expected to dominate the growth of the target market, due to the rising demand to convert reduce drug development delays, as well as the availability of a huge amount of healthcare data.

Therapeutic Area Insights

On the basis of Therapeutic Area, New World Evidence Data Market is segmented into Oncology, Cardiovascular, and Immunology.

End-Users Insights

On the basis of End-Users, New World Evidence Data Market is segmented into Pharmaceuticals, Medical Devices, Payers, and Providers. The Pharmaceutical end-user segment is expected to dominate the growth of the target market due to the increasing importance of RWE studies during drug approvals.

Regional Insights:

On the basis of Region, the New World Evidence Data Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is expected to dominate the growth of the target market over the forecast period, owing to factors such as rising population, rising prevalence of chronic disorders, rapid growth in urbanization and healthcare industry, increasing government initiatives and improved research and development programs.

Report Scope:

Attribute	Details
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Component - Services and Dataset. By Therapeutic Area - Oncology, Immunology, and Cardiovascular. By End-Users - Pharmaceuticals, Medical Devices, Payers, and Providers.
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the New World Evidence Data Market report based on Component, Therapeutic Area, End-User, and Region:

New World Evidence Market, By Component:

• Datasets (Claims, Clinical, Pharmacy, Patients)
• Services

New World Evidence Market, By Therapeutic Area:

• Oncology
• Immunology
• Cardiovascular

New World Evidence Market, By End-Users:

• Pharmaceuticals
• Medical Devices
• Payers
• Providers

New World Evidence Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating the New World Evidence Data Market includes, Oracle Corporation, IQVIA Holdings, Inc., International Business Machines Corporation, Syneos Health, Inc., ICON Public Limited Company, Pharmaceutical Product Development LLC, Optum, Inc., Cognizant Technology Solutions Corp., SAS Institute, Inc., and Flatiron Health, Inc.

• Oracle Corporation *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• IQVIA Holdings, Inc.
• International Business Machines Corporation
• Syneos Health, Inc.
• ICON Public Limited Company
• Pharmaceutical Product Development LLC
• Optum, Inc.
• Cognizant Technology Solutions Corp.
• SAS Institute, Inc.
• Flatiron Health, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Recent Development:

• In October 2021, the Professional Society for Health Economics and Outcomes Research (ISPOR), in association with the International Society of Pharmacoepidemiology, the Duke-Margolis Centre for Health Policy, and the National Pharmaceutical Council, launched the Real-World Evidence Transparency Initiative. Real-world data (RWD) and real-world evidence (RWE) are being used more widely across the product life cycle, according to Deloitte's benchmarking research on RWE. For instance, biopharma firms increased the inclusion of RWE in regulatory filings beyond completing post-marketing obligations. RWD/E (Real World Data Evidence) was crucial in helping biopharma firms develop during the COVID-19 pandemic and quickly bring innovative vaccines and treatments for this highly infectious illness to market.
• In September 2019, IQVIA™ launched two of its capabilities in order to support clinical teams with greater ease. The features offered were tested, co-designed, and are now used by the top five pharmaceutical companies.

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Preview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snippet, By Component
     • Market Snippet, By Therapeutic Area
     • Market Snippet, By End- User
     • Market Snippet, By Region
   • Opportunity Map Analysis
3. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
4.  New World Evidence Data Market, By Component, 2024 – 2034, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
     • Y-o-Y Growth Analysis (%), 2024 – 2034
     • Segment Trends
   • Database
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
       • Claims
       • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
   • Clinical
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
     • Pharmacy
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034

• Patient
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
• Services
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034

 New World Evidence Data Market, By Therapeutic Area, 2024 – 2034, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
  • Y-o-Y Growth Analysis (%), 2024 – 2034
  • Segment Trends
• Oncology
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
• Cardiovascular
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
• Immunology
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034

 New World Evidence Data Market, By End- User, 2024 – 2034, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
  • Y-o-Y Growth Analysis (%), 2024 – 2034
  • Segment Trends
• Pharmaceuticals
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
• Medical Devices
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
• Payers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034
• Providers
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2024 – 2034

 New World Evidence Data Market, By Region, 2024 – 2034, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2024 – 2034
  • Y-o-Y Growth Analysis (%), 2024 – 2034
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Component, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Therapeutic Area, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By End- User, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn), By Component, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Therapeutic Area, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By End-User, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Component, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Therapeutic Area, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By End- User, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn), By Component, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Therapeutic Area, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By End- User, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Component, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Therapeutic Area, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By End-User, 2024 – 2034
  • Market Size and Forecast (US$ Bn), By Country, 2024 – 2034
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
2. Company Profiles
   •  
     • Oracle Corp.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • IQVIA Holdings, Inc.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • International Business Machines Corporation
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • ICON Public Limited Company
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Pharmaceutical Product Development LLC
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Optum, Inc.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Cognizant Technology Solutions Corp.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • SAS Institute, Inc.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview
     • Flatiron Health, Inc.
       • Company Overview
       • Product Portfolio
       • Key Highlights
       • Financial Overview

Section

• Research Methodology
• About Us
• Contact